second was a significant predictor of grade 2 RP in multivariate analysis (P ¼ 0.043). The ratio of CD4 and CD8 cells has a tendency to predict grade 3 RP in multivariate analysis (P ¼ 0.053).There was a moderate correlation between the preexisting ILAs score on CT findings and the grade of RP (Pearson Correlation Coefficient ¼ 0.364, P ＜ 0.001). Conclusion: Preexisting radiological ILAs is associated with an increased risk of grade 2 RP and grade 3 RP after TRT in patients with LS-SCLC.
Background: Previous studies have demonstrated that prophylactic cranial irradiation (PCI) can reduce the risk of brain metastases and prolong overall survival in patients with small cell lung cancer (SCLC). However, whether different characteristics of patients with extensive SCLC effects the efficacy and safety of PCI remains controversial. This meta-analysis aims to test the efficacy and safety of PCI in patients with extensive SCLC. Method: PubMed, EmBase, and the Cochrane Library were searched for relevant studies published through 12 September 2017. Hazard ratios (HRs) were used to measure overall survival (OS) and progression free survival (PFS), and relative risks (RRs) were employed to calculate brain metastases, survival rate, and adverse events. Summary results were pooled using the random-effect model. Result: Of 1,124 identified citations, we included 13 trials reporting on 1,286 patients with extensive SCLC. PCI did not associate with significantly improved OS (HR: 0.82; 95%CI: 0.60-1.11; P¼0.192) or PFS (HR: 0.82; 95%CI: 0.68-1.00; P¼0.052) compared with patients not receiving PCI, while PCI did associate with significantly decreased brain metastases (RR: 0.54; 95%CI: 0.41-0.72; P<0.001). We noted further that PCI significantly increased the 1-year survival rate (RR: 1.50; 95% CI: 1.05-2.14; P¼0.027) while it had no significant effect on 2-(RR: 0.85; P¼0.387), 3-(RR: 0.74; P¼0.294), 4-(RR: 0.49; P¼0.053), or 5year survival rates (RR: 0.59; P¼0.522) compared with the non-PCI group. Finally, increased adverse events including fatigue, dermatitis, anorexia, nausea, vomiting, malaise, and cognitive functioning were found in the PCI group. Conclusion: The findings of this meta-analysis suggest that patients with extensive SCLC who receive PCI can reduce the risk of brain metastases and increase their 1-year survival rate. However, PCI is associated with a significantly increased risk of adverse events. Background: ALK positive NSCLC is estimated to account for 1,600 cases per year in England. Brigatinib is a next generation ALK inhibitor with proven efficacy after crizotinib but its role in 1st line is still under investigation. If licensed in Europe it may further extend survival for this rare group of patients. Method: We conducted a multicentre retrospective study across hospitals from the National Health System (NHS) in England on ALK positive patients who were offered treatment with the newer generations of ALK inhibitors. For this analysis, patients who received treatment with brigatinib through Compassionate use program or clinical trials between 2012 and 2018 were selected. The primary aims were time of exposure to brigatinib (as a surrogate of clinical benefit) and the objective response rate (ORR). The secondary aim was the incidence of grade 3-4 toxicity. And an exploratory aim analysed the value of ALK inhibitors treatment sequence. Result: A total of 30 patients with an ALK positive lung adenocarcinoma were included with a median age of 50 years. 53% of patients were female and 77% never smoked. 90% presented at diagnosis with metastatic disease and 63% developed brain metastasis. The median follow-up time since the start of brigatinib was 9.7 months and 53% of patients were on brigatinib at the time of analysis. In 57% of cases brigatinib was only used after a 2 nd line of treatment. Only 6 patients were treated in the first line setting. The overall median time of exposure was 12.1 months (95% CI, 4.7 to 19.6) with a maximum exposure of 30 months. The ORR was 50% within the 28 evaluable patients. Median overall survival was not reached. Only 1 patient had grade 3-4 toxicity with increased AST. The use of brigatinib in 1s t and 2nd lines (13 patients) did not reach a median exposure time and the ORR was 69%. Brigatinib post-crizotinib (9 patients) had a higher exposure time compared with post-ceritinib (13 patients), respectively, 9.1 (95% CI, 0.5 to 25.7) and 6.6 months (95% CI, 2.6 to 10.6). However the first sequence was more often used in 1 st /2 nd lines (50% vs 15%). Conclusion: Brigatinib is an active and very well tolerated drug. Despite being used mainly in heavily pre-treated patients, our data confirm a meaningful clinical benefit in this population. Its efficacy may be higher in earlier lines and we found no clear signal favouring a specific sequence of treatment Background: Brain metastases from non-small cell lung cancer is often regarded as the ominous sign of disease progression . In the ALKtranslocated population, brain metastases are seen in a higher incidence, either at diagnosis or as a common site of progression for patients receiving tyrosine kinase inhibitors (TKI). The management of brain metastases in this population remains a challenge since several methods of treatment are available. TKI-treatment, especially with second or third generation drugs can be effective but the role of radiation therapy, with either whole brain radiotherapy (wbrt) or stereotactic radiosurgery (srs), has not been fully elucidated. A retrospective study was conducted at ou Institution in order to evaluate the frequency of brain metastases in this subggroup of patients and in order to explore clinical features associated with survival.
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